Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial
- PMID: 40281208
- DOI: 10.1038/s41409-025-02566-6
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial
Conflict of interest statement
Competing interests: The authors declare no competing interests.
References
-
- Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007. https://pubmed.ncbi.nlm.nih.gov/17784964/ .
-
- Al-Homsi AS, Cirrone F, Wo S, Cole K, Suarez-Londono JA, Gardner SL, et al. PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023;7:3604–11. https://pubmed.ncbi.nlm.nih.gov/37163349/ . - DOI - PubMed - PMC
-
- Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96. https://pubmed.ncbi.nlm.nih.gov/23075175/ . - DOI - PubMed
-
- Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4:3913–25. https://pubmed.ncbi.nlm.nih.gov/32813874/ . - DOI - PubMed - PMC
-
- Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A Phase I/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia/lymphoma. Transpl Cell Ther. 2021;27:928.e1–e7. https://pubmed.ncbi.nlm.nih.gov/34274491/ . - DOI
Publication types
LinkOut - more resources
Full Text Sources
